Abstract
In 2002 the first transcatheter aortic valve implantation (TAVI) was performed in Europe. Since this time, TAVI has become increasingly utilised both across Europe and worldwide. With the early trials now reporting encouraging mid- to late-term results, TAVI has become a cost-effective alternative in high-risk patients not amenable to open surgery. Indeed, these indications look likely to become further expanded into a wider range of patient groups as we gain further technical familiarity alongside the development of novel generations of valve and advances in transcatheter technology. This chapter discusses the evolution of TAVI in Europe, summarising the route leading up to its incorporation into routine clinical practice and the potential for future development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Berland J, Cribier A, Savin T, Lefebvre E, Koning R, Letac B. Percutaneous balloon valvuloplasty in patients with severe aortic stenosis and low ejection fraction. Immediate results and 1-year follow-up. Circulation. 1989;79:1189–96.
Cribier A, Savin T, Saoudi N, Rocha P, Berland J, Letac B. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet. 1986;1:63–7.
Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8.
Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Sebagh L, et al. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43:698–703.
Cribier A, Eltchaninoff H, Tron C. First human transcatheter implantation of an aortic valve prosthesis in a case of severe calcific aortic stenosis. Ann Cardiol Angeiol (Paris). 2003;52:173–5.
Cribier A, Eltchaninoff H, Tron C, Bauer F, Agatiello C, Nercolini D, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol. 2006;47:1214–23.
Edwards_Lifesciences. Edwards Lifesciences to Acquire Percutaneous Valve Technologies, Inc. for $125 Million. http://www.edwards.com/newsroom/Pages/nr20031215.aspx.
Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006;114:1616–1624.
Grube E, Laborde JC, Zickmann B, Gerckens U, Felderhoff T, Sauren B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv. 2005;66:465–9.
Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451–96.
van Mieghem NM, Head SJ, van der Boon RM, Piazza N, de Jaegere PP, Carrel T, et al. The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosis. EuroIntervention. 2012;8:258–66.
NICE. Transcatheter aortic valve implantation for aortic stenosis. NICE interventional procedure guideline [IPG421]; 2012. https://www.nice.org.uk/guidance/ipg421.
Mylotte D, Osnabrugge RL, Windecker S, Lefevre T, de Jaegere P, Jeger R, et al. Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J Am Coll Cardiol. 2013;62:210–9.
Schymik G, Lefevre T, Bartorelli AL, Rubino P, Treede H, Walther T, et al. European experience with the second-generation edwards SAPIEN XT transcatheter heart valve in patients with severe aortic stenosis: 1-year outcomes from the SOURCE XT registry. JACC Cardiovasc Interv. 2015;8:657–69.
Ludman PF, Moat N, de Belder MA, Blackman DJ, Duncan A, Banya W, et al. Transcatheter aortic valve implantation in the United Kingdom: temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation. 2015;131:1181–90.
Beckmann A, Hamm C, Figulla HR, Cremer J, Kuck KH, Lange R, et al. The German Aortic Valve Registry (GARY): a nationwide registry for patients undergoing invasive therapy for severe aortic valve stenosis. Thorac Cardiovasc Surg. 2012;60:319–25.
Hamm CW, Mollmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, et al. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J. 2014;35:1588–98.
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.
Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.
Fairbairn TA, Meads DM, Hulme C, Mather AN, Plein S, Blackman DJ, et al. The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Heart. 2013;99:914–20.
Watt M, Mealing S, Eaton J, Piazza N, Moat N, Brasseur P, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart. 2012;98:370–6.
van Baal P. Important cost categories not included: transcatheter aortic valve implantation probably less cost-effective. Heart. 2012;98:1182.
NICE. Transcatheter valve-in-valve implantation for aortic bioprosthetic valve dysfunction. NICE interventional procedure guideline [IPG504]; 2014. https://www.nice.org.uk/guidance/ipg504/chapter/1-recommendations.
Piazza N, Kalesan B, van Mieghem N, Head S, Wenaweser P, Carrel TP, et al. A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients. JACC Cardiovasc Interv. 2013;6:443–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Austria, part of Springer Nature
About this chapter
Cite this chapter
Harling, L., Chukwuemeka, A. (2019). TAVI: A European Perspective. In: Stanger, O., Pepper, J., Svensson, L. (eds) Surgical Management of Aortic Pathology. Springer, Vienna. https://doi.org/10.1007/978-3-7091-4874-7_55
Download citation
DOI: https://doi.org/10.1007/978-3-7091-4874-7_55
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-4872-3
Online ISBN: 978-3-7091-4874-7
eBook Packages: MedicineMedicine (R0)